Investigating Isoflavone-adaptation Synthetic Compounds For Treating Skin Inflammation Disease: Cell-based Evaluation Of Bioactivity And Potential

Abstract

Psoriasis is an autoimmune skin disorder that has impacted the global population from children to adults. Psoriasis is characterized by unusual proliferation of keratinocytes, leading to itchy, bleeding, scaly, and red lesions due to increased immune system activity. Existing topical treatments often result in side effects, emphasizing the necessity for advanced drug discovery in managing psoriasis. A natural compound such as Flavonoids or Isoflavone from natural products is believed to demonstrate therapeutic properties for psoriasis. However, natural extracts are costly and yield limited quantities. To address this challenge, researchers perform synthetic modifications. The synthetic modifications can enhance the pharmacology activity and improve the physical characteristics of potential therapeutic agents. Thus, this study aims to evaluate the potential compounds particularly Isoflavone-modified synthetic compounds through examination of their anti-inflammatory efficacy and cytotoxic activity using CCK-8 as the cytotoxicity assay and ELISA to evaluate the cytokine produced by the treated cells by employing the THP-1 as the cellular model for assessment. This project discovered that CYR-6811k (40 µM), CYR-6812l (20µM), CYR-6813m (20 µM) out of 9 other compounds could inhibit the proinflammatory cytokine, specifically IL-6. However further studies must be conducted to evaluate the concentration of other cytokines contained in the cells treated with this Isoflafone -modified synthetic compound.